Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Daily Mirror
Daily Mirror
Sport
James Whaling

Cardiff City announce defender Sol Bamba is suffering from Non-Hodgkin lymphoma

Cardiff City have confirmed defender Sol Bamba is suffering from Non-Hodgkin lymphoma.

Bamba, 35, has immediately begun a course of chemotherapy, the club have announced.

He will continue to support his teammates at matches and continue his coaching development within the Bluebirds' academy.

Cardiff said in a statement: "We are saddened to inform supporters that Sol Bamba has been diagnosed with Non-Hodgkin lymphoma.⁣

"With the close support of the Club's medical team, Sol has immediately started a course of chemotherapy treatment.⁣

"Universally admired by teammates, staff and supporters in the Welsh capital, Sol has begun his battle in typically positive spirits and will continue to be an integral part of the Bluebirds family.

Bamba will immediately undergo a course of chemotherapy (REUTERS)

"During treatment, Sol will support his teammates at matches and our younger players within the Academy, with whom he will continue his coaching development.⁣

"All future updates on Sol’s progress will be provided only via official Club channels. While we request privacy for him and his family at this time, messages of support to be passed on to Sol may be sent to club@cardiffcityfc.co.uk.⁣

"We are all with you, Sol."

Bamba has been at Cardiff since 2016 having previously played for Leeds and Leicester in the English leagues.

The 46-cap Ivory Coast international has also represented Paris Saint-Germain, Dunfermline, Hibernian, Trabzonspor and Palermo.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.